Tolerability and safety of extemporaneously prepared oral methotrexate suspension in pediatric acute lymphoblastic leukemia: Experience from a comprehensive cancer center in Jordan
Prospective observational study evaluates safety and tolerability of oral methotrexate in pediatric ALL, suggesting a viable alternative.
Key Points
Evaluate the tolerability and safety of an extemporaneously prepared oral methotrexate suspension in pediatric ALL patients during maintenance therapy.
Prospective observational study conducted over eight months (February-September 2025)
Included pediatric ALL patients receiving compounded methotrexate suspension (2.5 mg/mL)
Tolerability assessed using the Methotrexate Intolerance Severity Score questionnaire.
One hundred patients included (mean age 4.8 years; 61% male)
Post-dose stomach pain, nausea, and vomiting occurred in 13%, 18%, and 9%, respectively
Moderate-to-severe intolerance was identified in 9% of patients.